The short-term efficacy and safety of injection of botulinum toxin A for female urethral pain syndrome
10.3760/cma.j.cn112330-20220220-00057
- VernacularTitle:A型肉毒毒素注射治疗女性尿道疼痛综合征的短期疗效和安全性
- Author:
Mengzhu LIU
1
;
Liao PENG
;
Hong SHEN
;
Deyi LUO
Author Information
1. 四川大学华西医院泌尿外科 四川大学华西泌尿外科研究所，成都 610041
- Keywords:
Urethral pain syndrome;
Botulinum toxin A;
Urethral syndrome
- From:
Chinese Journal of Urology
2023;44(12):927-929
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of injection of botulinum toxin A (BTX-A) for female urethral pain syndrome (UPS).Methods:This study retrospectively included 8 women with UPS who were treated by injection of BTX-A in West China Hospital of Sichuan University from February 2021 to September 2021. The average age was (47.87±11.33) years old, the median disease duration was 3(1.0, 10.8) years. Before treatment, The visual analogue scale (VAS) was (5.38±1.92), the Pain, Urgency, Frequency score (PUF) was (10.75±5.12), and the female sexual function index (FSFI) was (14.53±11.63). 100U BTX-A was injected at the 3, 6, 9, and 12 o'clock positions of the urethral meatus, as well as at the mid-urethra and the left and right sides of the bladder neck, totaling 10 injections. The VAS, PUF score, FSFI score, and complications were recorded at 1, 3, and 6 months after treatment.Results:The VAS score decreased to (3.25±2.12), (2.88±2.23)and(2.88±2.23) at 1, 3, and 6 months, showing statistically significant differences compared to the pre-treatment scores ( P<0.05); post-treatment PUF score declined to (6.63±3.93), (6.25±4.03)and(5.13±3.31), respectively, with only the 6-month score showing a statistically significant difference compared to the pre-treatment score ( P=0.03). The FSFI score increased slightly to (14.68±11.56), (16.76±12.17) and (16.76±12.17)at 1, 3, and 6 months post-injection, respectively, with no statistically significant differences compared to the pre-treatment scores ( P>0.05). Only 1 patient had transient dysuria. Conclusion:BTX-A injection is a safe and effective treatment for UPS, and it can be used for UPS patients who are unresponsive to conservative therapy.
